Guidance
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards, technical committees and working groups
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
MiE WP26-27 Consultation - Potential Research Topics only
MiE WP26-27 Consultation and context pointers
MiE WP26-27 Consultation with pointers to WP25-27 consultation
MiE KPIs
Relevant (future) calls
EU-Programme-Call
NACE code
EFFRA Organisations - members
EFFRA WG pointers
Pathways
Pathways
Projects
Projects
Resources
Resources
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
Structured Wiki
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.0. Cross-cutting call topics
H2020-Adhoc-2014-20
H2020-HCO-2014
H2020-IBA-SC1-BIOMEDICAL-2017
H2020-IBA-SC1-CORONAVIRUS-2020-4
H2020-IBA-SC1-eHealth-2017
H2020-IBA-SC1-Presidency-2020
H2020-JTI-IMI2-2015-08-single-stage
H2020-JTI-IMI2-2020-20-two-stage
H2020-JTI-IMI2-2020-22-single-stage
H2020-JTI-IMI2-2020-23-two-stage
H2020-PHC-2014-single-stage
H2020-SC1-2020-Single-Stage-RTD
H2020-SC1-2020-Two-Stage-RTD
H2020-SC1-DTH-2020-1
H2020-SC1-FA-DTS-2020-1
H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT
H2020-SC1-PHE-CORONAVIRUS-2020-2-RTD
H2020-SMEINST-1-2014
H2020-SMEINST-2-2014
H2020-SMEINST-2-2015
H2020-SMEINST-2-2016-2017
H2020-EU.3.1.1. Understanding health, wellbeing and disease
H2020-HCO-2014
H2020-PHC-2014-two-stage
H2020-PHC-2015-two-stage
H2020-SC1-2016-RTD
H2020-SC1-2017-Single-Stage-RTD
H2020-SC1-2017-Two-Stage-RTD
H2020-SC1-2018-Single-Stage-RTD
H2020-SC1-2019-Single-Stage-RTD
H2020-SC1-2019-Two-Stage-RTD
H2020-EU.3.1.2. Preventing disease
H2020-PHC-2014-single-stage
H2020-PHC-2014-two-stage
H2020-PHC-2015-single-stage_RTD
H2020-PHC-2015-two-stage
H2020-SC1-2016-RTD
H2020-SC1-2017-Two-Stage-RTD
H2020-SC1-2018-Single-Stage-RTD
H2020-SC1-2019-Single-Stage-RTD
H2020-SC1-2019-Two-Stage-RTD
H2020-SGA-SC1-CEPI-2019
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-EU.3.1.3.2. Transferring knowledge to clinical practice and scalable innovation actions
H2020-EU.3.1.4. Active ageing and self-management of health
H2020-EU.3.1.4.0. Cross-cutting call topics
H2020-EU.3.1.4.1. Active ageing, independent and assisted living
H2020-EU.3.1.4.2. Individual awareness and empowerment for self-management of health
H2020-EU.3.1.5. Methods and data
H2020-EU.3.1.5.0. Cross-cutting call topics
H2020-EU.3.1.5.1. Improving halth information and better use of health data
H2020-EU.3.1.5.2. Improving scientific tools and methods to support policy making and regulatory needs
H2020-EU.3.1.5.3. Using in-silico medicine for improving disease management and prediction
H2020-EU.3.1.6. Health care provision and integrated care
H2020-EU.3.1.6.0. Cross-cutting call topics
H2020-EU.3.1.6.2. Optimising the efficiency and effectiveness of healthcare provision and reducing inequalities by evidence based decision making and dissemination of best practice, and innovative technologies and approaches
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-EU.3.1.7.1. Antimicrobial resistance
H2020-EU.3.1.7.12. Vaccine
H2020-EU.3.1.7.13. Other
H2020-EU.3.1.7.4. Diabetes
H2020-EU.3.1.7.5. Neurodegenerative diseases
H2020-EU.3.1.7.6. Psychiatric diseases
H2020-EU.3.1.7.8. Immune-mediated diseases